397 related articles for article (PubMed ID: 29932943)
1. Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.
Shen JP; Ideker T
J Mol Biol; 2018 Sep; 430(18 Pt A):2900-2912. PubMed ID: 29932943
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinase A, a synthetic lethal target for precision cancer medicine.
Mou PK; Yang EJ; Shi C; Ren G; Tao S; Shim JS
Exp Mol Med; 2021 May; 53(5):835-847. PubMed ID: 34050264
[TBL] [Abstract][Full Text] [Related]
3. Precision Oncology Decision Support: Current Approaches and Strategies for the Future.
Kurnit KC; Dumbrava EEI; Litzenburger B; Khotskaya YB; Johnson AM; Yap TA; Rodon J; Zeng J; Shufean MA; Bailey AM; Sánchez NS; Holla V; Mendelsohn J; Shaw KM; Bernstam EV; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2018 Jun; 24(12):2719-2731. PubMed ID: 29420224
[TBL] [Abstract][Full Text] [Related]
4. Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.
Benfatto S; Serçin Ö; Dejure FR; Abdollahi A; Zenke FT; Mardin BR
Mol Cancer; 2021 Aug; 20(1):111. PubMed ID: 34454516
[TBL] [Abstract][Full Text] [Related]
5. The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine.
Ozturk K; Dow M; Carlin DE; Bejar R; Carter H
J Mol Biol; 2018 Sep; 430(18 Pt A):2875-2899. PubMed ID: 29908887
[TBL] [Abstract][Full Text] [Related]
6. Mapping the landscape of synthetic lethal interactions in liver cancer.
Yang C; Guo Y; Qian R; Huang Y; Zhang L; Wang J; Huang X; Liu Z; Qin W; Wang C; Chen H; Ma X; Zhang D
Theranostics; 2021; 11(18):9038-9053. PubMed ID: 34522226
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
8. Genomics and bioinformatics as pillars of precision medicine in oncology.
Canzoneri R; Lacunza E; Abba MC
Medicina (B Aires); 2019; 79(Spec 6/1):587-592. PubMed ID: 31864231
[TBL] [Abstract][Full Text] [Related]
9. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
Srivas R; Shen JP; Yang CC; Sun SM; Li J; Gross AM; Jensen J; Licon K; Bojorquez-Gomez A; Klepper K; Huang J; Pekin D; Xu JL; Yeerna H; Sivaganesh V; Kollenstart L; van Attikum H; Aza-Blanc P; Sobol RW; Ideker T
Mol Cell; 2016 Aug; 63(3):514-25. PubMed ID: 27453043
[TBL] [Abstract][Full Text] [Related]
10. Predicting synthetic lethal interactions using conserved patterns in protein interaction networks.
Benstead-Hume G; Chen X; Hopkins SR; Lane KA; Downs JA; Pearl FMG
PLoS Comput Biol; 2019 Apr; 15(4):e1006888. PubMed ID: 30995217
[TBL] [Abstract][Full Text] [Related]
11. A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine.
Dotolo S; Marabotti A; Rachiglio AM; Esposito Abate R; Benedetto M; Ciardiello F; De Luca A; Normanno N; Facchiano A; Tagliaferri R
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34050359
[TBL] [Abstract][Full Text] [Related]
12. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.
Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethality: a step forward for personalized medicine in cancer.
Jariyal H; Weinberg F; Achreja A; Nagarath D; Srivastava A
Drug Discov Today; 2020 Feb; 25(2):305-320. PubMed ID: 31811941
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethality-mediated precision oncology via the tumor transcriptome.
Lee JS; Nair NU; Dinstag G; Chapman L; Chung Y; Wang K; Sinha S; Cha H; Kim D; Schperberg AV; Srinivasan A; Lazar V; Rubin E; Hwang S; Berger R; Beker T; Ronai Z; Hannenhalli S; Gilbert MR; Kurzrock R; Lee SH; Aldape K; Ruppin E
Cell; 2021 Apr; 184(9):2487-2502.e13. PubMed ID: 33857424
[TBL] [Abstract][Full Text] [Related]
15. Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility.
Ku AA; Hu HM; Zhao X; Shah KN; Kongara S; Wu D; McCormick F; Balmain A; Bandyopadhyay S
Nat Commun; 2020 May; 11(1):2375. PubMed ID: 32398776
[TBL] [Abstract][Full Text] [Related]
16. Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data.
Sinha S; Thomas D; Chan S; Gao Y; Brunen D; Torabi D; Reinisch A; Hernandez D; Chan A; Rankin EB; Bernards R; Majeti R; Dill DL
Nat Commun; 2017 May; 8():15580. PubMed ID: 28561042
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Genomics and Functional Genomics to Inform Clinical Decisions in IR.
Schachtschneider KM; Gaba RC
J Vasc Interv Radiol; 2018 Aug; 29(8):1117-1121. PubMed ID: 30055782
[No Abstract] [Full Text] [Related]
18. A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling.
Piyawajanusorn C; Nguyen LC; Ghislat G; Ballester PJ
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34368843
[TBL] [Abstract][Full Text] [Related]
19. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
[TBL] [Abstract][Full Text] [Related]
20. Preface on application of omics technologies in cancer biology and therapy.
Georgakilas AG
Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153
[No Abstract] [Full Text] [Related]
[Next] [New Search]
